Medifast Reports Q3 2026 Revenue Decline Amid Strategic Shift to Metabolic Health
Medifast (MED) reported a 19.4% decline in third-quarter revenue, totaling $72 million, driven largely by a 47.7% decrease in active earning coaches. The company is currently navigating a significant business model transition toward metabolic health under its Trilivy brand, facing headwinds from the rapid market adoption of GLP-1 medications which has impacted traditional weight loss coaching numbers. Despite the revenue drop and a net loss of $17.5 million, Medifast achieved record coach productivity with average revenue per coach increasing by 54.1%. The company is executing its 'Project Catalyst' restructuring program to optimize costs through facility closures and software updates. Management has provided fourth-quarter guidance aiming for a return to profitability, targeting earnings between $0.00 and $0.25 per share.
Tickers: $MED
Topics: Financial guidance GLP-1 impact Net loss Restructuring charges Revenue decline
Read the full article at Motley Fool
Part of the story Travelzoo Reports Q3 2026 Revenue Growth Amid Strategic Shift to Membership Model (4 articles)